Mucositis Management

Initial Assessment and Grading

• The World Health Organization recommends grading mucositis using the WHO scale to guide management intensity, with grades ranging from 0 (no visible erythema or ulceration) to 3 (ulceration persisting ≥7 days) 1
• Patients with leucopenia have a significantly higher infection risk (P = 0.005), making fungal and bacterial superinfection critical considerations 1, 2
• The American Society of Clinical Oncology suggests documenting the average oropharyngeal pain score over the last 24 hours on a 0-10 scale, with scores ≥6 indicating severe pain 1

Basic Oral Care Protocol

• The Multinational Association of Supportive Care in Cancer recommends implementing frequent non-medicated saline mouth rinses 4-6 times daily as the cornerstone of management 3, 4
• The European Society for Medical Oncology suggests using plain water for chemotherapy/radiation-induced mucositis, but switching to saline-containing mouthwashes for targeted therapy-associated mucositis due to higher microbial burden 1
• The American Dental Association recommends using a soft toothbrush replaced regularly 3, 4
• The American Society of Clinical Oncology strictly advises against using alcohol-based mouth rinses as they irritate damaged mucosa and worsen symptoms 5, 6

Pain Management Algorithm

• The National Comprehensive Cancer Network recommends initiating topical morphine 0.2% mouthwash as first-line treatment for Grade 2-3 mucositis (Level III evidence) 7, 6
• The American Society of Clinical Oncology suggests using 0.5% doxepin mouthwash for general mucositis pain (Level IV evidence) 7, 6
• The European Society for Medical Oncology recommends escalating immediately to patient-controlled analgesia with morphine for severe pain (Grade 3-4) or pain uncontrolled by topical measures (Level I-II evidence) 3, 4, 7, 5, 6

Dietary Modifications and Nutritional Support

• The American Society for Parenteral and Enteral Nutrition recommends eliminating all painful food stimuli, including smoking, alcohol, tomatoes, citrus fruits, hot drinks, and spicy, hot, raw, or crusty foods 7, 5, 6
• The European Society for Clinical Nutrition and Metabolism suggests initiating early enteral nutrition if swallowing difficulties develop 1, 8, 5, 6
• The American Society of Clinical Oncology recommends screening all patients for nutritional risk due to high risk of malnutrition following cancer therapy 1, 8, 5, 6

Prevention Strategies

• The American Society for Radiation Oncology recommends using benzydamine oral rinse for moderate-dose radiation therapy (up to 50 Gy) without concurrent chemotherapy (Level I evidence) 3, 4, 7, 5
• The European Society for Medical Oncology suggests using oral cryotherapy for 30 minutes for bolus 5-FU chemotherapy (Level II evidence) 3, 4, 7, 5, 6
• The American Society of Clinical Oncology recommends using palifermin (keratinocyte growth factor-1) 60 μg/kg/day for 3 days before conditioning and 3 days post-transplant for patients with hematological malignancies receiving high-dose chemotherapy and total body irradiation with autologous stem cell transplantation (Level I-II evidence) 3, 7, 5, 6

Interventions to AVOID

• The American Society of Clinical Oncology recommends against using chlorhexidine mouthwash for prevention or treatment of established mucositis (Level II-III evidence against) 3, 4, 7, 5, 6, 2
• The European Society for Medical Oncology suggests against using sucralfate for treatment of radiation-induced or chemotherapy-induced oral mucositis (Level I-II evidence against) 3, 4, 5, 6, 2
• The National Comprehensive Cancer Network recommends against using antimicrobial lozenges (PTA, BCoG) for prevention of radiation-induced mucositis (Level II evidence against) 3, 4, 7, 5, 2
• The American Society of Clinical Oncology advises against using GM-CSF mouthwash (Level II evidence against) 6, 2
• The European Society for Medical Oncology recommends against using acyclovir and analogues for prevention with standard-dose chemotherapy (Level II evidence against) 3

Management of Radiation‑Induced Throat Pain in Week 3 of Head‑and‑Neck Radiotherapy

Immediate Pain Management

• Topical morphine 0.2 % mouthwash is recommended as first‑line therapy for moderate‑to‑severe throat pain (Grade 2‑3 mucositis) in patients receiving chemoradiation for head‑and‑neck cancer. Level II evidence. [9][10][11][12]
• If relief from topical morphine is insufficient, add 0.5 % doxepin mouthwash as an adjunct for additional analgesia. Level II evidence. [9][10][11][12]
• Escalate to patient‑controlled systemic morphine (PCA) when pain remains uncontrolled or when Grade 3‑4 mucositis causes severe functional impairment. Level I evidence. [13][14]
• Transdermal fentanyl may be used as an alternative systemic opioid for severe pain when oral opioids are not feasible. Level II evidence. 15

Essential Basic Oral Care

• Perform non‑medicated saline rinses 4–6 times daily to maintain mucosal hydration, remove debris, and reduce inflammation. Level II evidence. [13][14]
• Use a soft‑bristled toothbrush, replaced regularly, to preserve oral hygiene without traumatizing damaged mucosa. Level II evidence. [13][14]
• Avoid alcohol‑based mouth rinses because they irritate injured mucosa and worsen symptoms. Level II evidence. [13][14]
• Topical lidocaine viscous can be employed for short‑term breakthrough pain relief on an empiric basis. Level III evidence. [13][14]

Dietary Modifications & Nutritional Support

• Eliminate painful food stimuli (e.g., smoking, alcohol, acidic fruits, hot/spicy/raw/crusty foods) to reduce mucosal irritation. Level II evidence. [9][15]
• Screen all patients in week 3 of radiotherapy for nutritional risk, as malnutrition is common in this phase. Level II evidence. [13][14]
• Initiate early enteral nutrition (e.g., feeding tube) promptly when swallowing difficulties arise, especially in older adults. Level II evidence. [13][14]

Interventions to Avoid (Strong Evidence Against)

Preventive Strategies for the Remaining Treatment Course

• Benzydamine mouthwash is advised for prevention of oral mucositis in patients receiving moderate‑dose radiation (≤ 50 Gy) without concurrent chemotherapy. Level I evidence. [13][9][10][11][12][14][15][16][17][18]
• Low‑level laser therapy (≈ 632.8 nm) may be beneficial for mucositis prevention in radiotherapy without concurrent chemotherapy. Level III evidence. [9][10][11][12]15
• Employ midline radiation blocks and three‑dimensional treatment planning to reduce mucosal injury. Level II evidence. [13][14][16][17]18

Common Pitfalls to Avoid

• Continuing to use chlorhexidine or sucralfate based on outdated protocols, despite strong evidence against their use in radiation‑induced mucositis. Level II‑III evidence. [13][9][10][11][12][14][16][17]18
• Inadequate pain assessment and delayed escalation to systemic opioids; validated 0‑10 pain scales should be used, with scores ≥ 6 prompting immediate systemic opioid therapy. Level II evidence. [13][14]
• Failure to screen for nutritional risk and delayed feeding‑tube placement, leading to malnutrition, treatment interruptions, and poorer outcomes, particularly in older patients. Level II evidence. [13][14]